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Abstract. microRNA (miR/miRNA) are small non-coding 
RNAs that control gene expression at the post-transcriptional 
level by targeting mRNAs. Aberrant expression of miRNAs 
is often observed in different types of cancer. Specific 
miRNAs function as tumor suppressors or oncogenes and 
interfere with various aspects of carcinogenesis, including 
differentiation, proliferation and invasion. Upregulation of 
miRNAs 221 and 222 has been shown to induce a malignant 
phenotype in numerous human cancers via inhibition of 
phosphatase and tensin homolog (PTEN) expression. Neuro-
blastoma is the most common extracranial solid malignancy 
in children, which is characterized by cellular heterogeneity 
that corresponds to different clinical outcomes. The different 
cellular phenotypes are associated with different gene muta-
tions and miRs that control genetic and epigenetic factors. For 
this reason miRs are considered a potential therapeutic target 
in neuroblastoma. The aim of the present study was to inves-
tigate the mechanisms by which extracellular high mobility 
group box 1 (HMGB1) promotes cell growth in neuroblas-
toma. SK-N-BE(2) and SH-SY5Y neuroblastoma derived cell 
lines were transfected with the antisense oligonucleotides, 
anti-miR-221 and -222, followed by treatment with HMGB1 
to investigate the expression of the oncosuppressor PTEN. In 
this study, it was demonstrated that HMGB1, which is released 
by damaged cells and tumor cells, upregulates miR-221/222 
oncogenic clusters in the two human neuroblastoma derived 
cell lines. The results revealed that the oncogenic cluster 
miRs 221/222 were more highly expressed by the most 
undifferentiated cell line [SK-N-BE(2)] compared with the 
the less tumorigenic cell line (SH-SY5Y) and that exogenous 
HMGB1 increases this expression. In addition, HMGB1 
modulates PTEN expression via miR-221/222, as demon-
strated by transiently blocking miR-221/222 with anti-sense 
oligonucleotides. These results may lead to the development 
of novel therapeutic strategies for neuroblastoma.
Introduction
Neuroblastoma arises from neural crest precursors that do 
not differentiate into terminal neurons. The hallmark of these 
tumors are the numerous different clinical variables, ranging 
from highly metastatic with rapid progression and resistance 
to therapy to spontaneous regression or development into 
benign ganglioneuromas (1). Neuroblastoma accounts for 
>7% of malignancies in pediatric patients (<15 years) (1). 
Approximately 65% of primary tumors occur in the adrenal 
glands. Tumors also arise in the neck, chest and pelvis. The 
symptoms of neuroblastoma are dependent on tumor loca-
tion, as well as the presence or absence of metastasis and 
paraneoplastic syndromes (1). At diagnosis, 40% of cases are 
classified as high-risk according to age of onset (<18 months) 
and the presence of genetic mutations (2). Despite advances 
in chemotherapy, 60% of high-risk neuroblastomas recur 
and thus mortality rates are extremely high (3). For low-risk 
patients, surgery alone is curative in the majority of cases, 
while intermediate-risk patients (without MYCN amplifi-
cation) are administered low doses of cyclophosphamide 
and vincristine until resection is possible (4). Treatments 
for high-risk patients with stage III and IV neuroblastoma 
include intensification of conventional chemotherapy agents 
with the addition of 13-cis-retinoic acid. Clinical trials with 
viral agents able to target tumor cells or immune therapies 
with exposure of neuroblastoma cells to interferon γ, prior 
to conventional chemotherapy, are returning encouraging 
results (5).
The different clinical variables correspond to genetic muta-
tions in crucial genes, including oncogenes, oncosuppressor 
genes and transcription factors. Furthermore, scientists are 
concentrating their efforts on determining the network of 
regulatory microRNAs (miRs/miRNAs) and genes in neuro-
blastoma (6,7). A possible therapeutic approach would be to 
enhance the expression of miRNAs that induce differentiation 
while suppressing those associated with tumor progression. 
As well as regulating the expression of oncogenes and tran-
scription factors, miRNAs are associated with epigenetic 
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mechanisms in neuroblastoma, such as DNA methylation and 
the induction of autophagy (8-10).
The key prognostic factor in neuroblastoma is MYCN 
amplification (11), which occurs in ~20% of cases and is asso-
ciated with poor outcome. MYCN amplification is correlated 
to the transcription of proteins that regulate differentiation, 
such as nestin (12), or HMG proteins, which suppress apop-
tosis, induce autophagy and amplify AKT signaling (13,14). 
A recent study demonstrated that high mobility group box 1 
(HMGB1) is upregulated in neuroblastoma (15), inducing 
cell proliferation and autophagy in Schwann cells. In our 
recent study, the HMGB1/receptor for advanced glycation end 
products (RAGE)/miR-221/222 signaling pathway, which is 
associated with cellular proliferation and phosphatase and 
tensin homolog (PTEN) inhibition, was identified in a model 
of thyroid cancer (16). In vitro models of neuroblastoma 
derive from different tumors, and maintain their heteroge-
neous genetic variances and, thus, tumorigenic properties. It 
is known that each neuroblastoma and its deriving cell line 
has at least three different phenotypic patterns that include 
stem, neuroblastic and non-neuronal cells. The different 
phenotypes show different tumorigenicity. Tumorigenicity in 
neuroblastoma is directly associated with MYCN amplifica-
tion and differently expressed miRNAs (17). Furthermore, 
numerous miRNAs induce neuroblastoma cell differentiation 
and interact with endogenous substances. The understanding 
of these interactions may provide novel strategies for the treat-
ment of neuroblastoma.
The present study reports the role of HMGB1 in an 
MYCN-amplified neuroblastoma cell line [SK-N-BE(2)] 
and a neuroblastoma cell line without MYCN amplification 
(SH-SY5Y). The results show that HMGB1 exerts different 
effects on the two cell lines and that its interaction with 
miR-221/222 influences important pathways associated with 
cell growth.
Materials and methods
Reagents. Anti-human PTEN monoclonal antibody 
(cat. no. M3627; 1:1,000 dilution) was obtained from Dako 
(Carpinteria, CA, USA). Monoclonal anti-mouse IgG horse-
radish peroxidase conjugate (cat. no. NXA931; 1:2,000 
dilution) was purchased from GE Healthcare (Little Chal-
font, UK). Monoclonal anti-human HMGB1 (cat. no. H9537; 
1:2,000) and β-actin (cat. no. A5316; 1:10,000) antibodies were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Human 
recombinant HMGB-1 expressed in Escherichia coli was from 
Sigma-Aldrich (cat no. H4652; St. Louis, MO, USA). miRIDIAN 
Hairpin Inhibitor hsa-miRNA-221 (cat. no. IH300578-07-
005) and hsa-miRNA-222 (cat. no. IH301176-02 -005) and 
miRIDIAN microRNA Hairpin Inhibitor Transfection 
Control with Dy547 (cat. no. FE5IP0045000105) (control 
oligonucleotide) and DharmaFECT 1 Transfection Reagent 
(cat. no. FE5T200103) were purchased from GE Health-
care Dharmacon Inc. (Lafayette, CO, USA). The mature 
miRNA-221 sequence was 5'-AGC UAC AUU GUC UGC UGG 
GUU UC-3' and the mature miRNA-222 sequence was 5'-CUC 
AGU AGC CAG UGU AGA UCCU-3'. Reverse transcription 
(RT) primers and TaqMan probes were obtained from TaqMan 
miRNA assays (Applied Biosystems, Foster City, CA, USA).
Cell lines. SK-N-BE(2) (DSMZ no. ACC632) and SH-SY5Y 
(DSMZ no. ACC209) cells were obtained from DSMZ 
(Braunschweig, Germany) in October 2012 and maintained 
in RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc.), 
supplemented with heat-inactivated 10% fetal calf serum 
(FCS) containing 2 mM L-glutamine. Where required, 10 nM 
HMGB1 was added to the cultures for 24, 48 or 72 h. Cell 
viability was determined by a trypan blue exclusion test. Cells 
were frozen in nitrogen liquid tanks (2x106 cells/ml FCS, 10% 
dimethylsulfoxide) until use between the 4th and 8th passage 
after revival.
Cell viability. Cell viability was determined using the Trypan 
blue exclusion test. SK-N-BE(2) or SH-SY5Y cells (5x104/ml) 
were suspended in a 10-µl suspension containing trypan blue 
(0.4% w/v; Sigma-Aldrich) in phosphate-buffered saline 
(PBS) and incubated at room temperature for 5 min, followed 
by examination under a light microscope to determine the 
percentage of cells with clear (viable cells) and blue cytoplasm 
(non-viable cells).
Knockdown of miRNA. AntagomiRs against miR-221 
and -222, and control oligonucleotide with Dy547 were tran-
siently transfected into SK-N-BE(2) and SH-SY5Y cells using 
DharmaFECT 1 Transfection Reagent, prior to treatment 
with HMGB1. Briefly, cells were seeded in 12-well plates at a 
density of 2x105 cells/well and incubated at 37˚C for 18 h prior 
to transfection. Subsequently, culture medium was replaced 
with 1 ml antibiotic-free medium containing DharmaFECT 1 
Transfection Reagent (2 µl/ml) and antagomiRs at a final 
concentration of 25 nM for 24 h, according to manufacturer's 
instructions. Controls with Dy547 and DharmaFECT 1 Trans-
fection Reagent alone were included in the experiments as 
indicators of transfection efficiency and as negative controls, 
respectively. Transfection efficiency was determined by 
cytofluorimetric readings in the red light spectrum (575 nm; 
Cytofluorimetric Coulter Epics XL; Beckman Coulter, Brea, 
CA, USA) and reached 69-76% in Dy547-positive cells.
Relative quantification of miRNA by RT‑quantitative poly‑
merase chain reaction (qPCR). Total RNA was extracted 
from SK-N-BE(2) and SH-SY5Y cells with TRIzol reagent 
(Life Technologies; Thermo Fisher Scientific, Inc.), according 
to the manufacturer's instructions. Briefly, 1 ml TRIzol and 
0.2 ml chloroform (Sigma-Aldrich) were added to pellets and 
centrifuged at 12,000 x g at 4˚C for 15 min. For the detection 
of mature miR-221 and -222, 50 ng total RNA was reverse 
transcribed using the TaqMan MicroRNA Reverse Transcrip-
tion kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). 
qPCR was performed using an miRNA-specific TaqMan 
assay (cat. no. PN4427975; Applied Biosystems; Thermo 
Fisher Scientific, Inc.) and hsa-miR221 and -222 and an ABI 
Prism 7900HT Sequence Detection System (Applied Biosys-
tems; Thermo Fisher Scientific, Inc.). PCR conditions were 
as follows: 50˚C for 2 min and 95˚C for 10 min, followed by 
40 cycles of 95˚C for 15 sec and 60˚C for 1 min. Amplifica-
tions were performed in triplicate and repeated twice. The 
ubiquitously expressed U6b small nuclear RNA was used for 
normalization. An experimental negative control (no cDNA) 
was used, which confirmed the absence of amplification. 
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Relative quantification of miRNA expression was performed 
using the ∆∆Cq method (18).
Western blot analysis. Briefly, whole cell lysates were heat 
denatured for 5 min, loaded on a standard Tris-HCl 12.5% 
SDS-PAGE gel, and run on ice at 40 V for the stacking gel 
and 80 V for the running gel to separate the proteins, as 
previously described (12). Proteins were transferred onto a 
previously activated PVDF membrane (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA). Membranes were then placed in 
Tris-buffered saline (Sigma-Aldrich) with Tween 20 and 5% 
bovine serum albumin (Sigma-Aldrich) for 1 h, and probed 
overnight with the specific antibody at 4˚C. At the end of 
incubation time, membranes were washed with Tris-buffered 
saline and incubated with anti-mouse IgG peroxidase conju-
gated secondary antibody (1:2,000 dilution) for 1 h at room 
temperature. Membranes were stripped with stripping buffer 
(β-mercaptoethanol, SDS and Tris-HCl) and incubated with 
β-actin monoclonal antibody as a loading control. Signals 
were detected by autoradiography (Kodak Biomax; Kodak, 
Rochester, NY, USA) using a chemiluminescent peroxidase 
substrate kit (Sigma-Aldrich), then quantified by densito-
metric analysis using Quantity-One software (version 4.6.5; 
Bio-Rad Laboratories, Inc.).
Cytofluorimetric determination of cell cycle. Parental control 
cells and transfectant cells (105) were seeded into a 6-well plate 
with and without 10 nM HMGB1. After 24 h, cells were fixed 
with cold 70% ethanol in PBS for 1 h at 4˚C. After centrifu-
gation at 200 x g for 10 min at 4˚C, cells were washed once 
in PBS. The pellet was resuspended in a solution of 0.5 ml 
propidium iodide (PI; 0.1 mg/1 ml in PBS; Sigma-Aldrich) and 
50 µl RNAse (Type I-A; 10 mg/ml in PBS; Sigma-Aldrich). 
PI-stained nuclei were incubated in the dark at room tempera-
ture for 15 min and maintained at 4˚C until the nuclear DNA 
content of the cells was evaluated by flow cytometry (Cyto-
fluorimetric Coulter Epics XL; Beckman Coulter).
Statistical analysis. All statistical analyses were performed 
using KaleidaGraph version 4.5.1 (Synergy Software Inc., 
Reading, PA, USA). All determinations were performed three 
times. Data are expressed as means + standard deviation. The 
differences between cell populations [SK-N-BE(2) cells and 
SH-SY5Y cells, untransfected or transfected with antagomiRs; 
untreated or treated with HMGB1] were analyzed for 
miR-221/222, HMGB1 and PTEN expression, using Student's 
t-test. P-values were evaluated in the differently treated cell 
populations. P<0.05 was considered to indicate a statistically 
significant difference.
Results
Effect of HMGB1 on miR‑221 and ‑222 expression in 
SK‑N‑BE(2) and SH‑SY5Y cells. Fig. 1 shows that the two 
cell lines express different amounts of miR-221 and -222. 
SK-N-BE(2) cells express markedly higher levels of miR-221 
(100-fold; P=0.004) and miR-222 (80-fold; P=0.007) than 
SH-SY5Y cells.
Treatment with 10 nM HMGB1 for 24 h increased expres-
sion of miR-221 and -222 in both SK-N-BE(2) and SH-SY5Y 
cells. By contrast, transfection of SK-N-BE2 cells with 
miR-221 and -222 antagomiRs reduced their expression by 
49% each compared with the controls. In transfected SH-SY5Y 
cells, expression was reduced by 41% for miR-221 and 40% for 
miR-222, compared with the controls.
The treatment of transfected cells (transfectants) with 
HMGB1 for 24 h did not markedly increase or decrease the 
expression of miR-221/222 in either cell line.
Expression of HMGB1 in parental control and transfectant 
SK‑N‑BE(2) and SH‑SY5Y cells. Endogenous HMGB1 protein 
was expressed in both cell lines (Fig. 2). While endogenous 
HMGB1 levels decreased in SK-N-BE(2) transfectants compared 
with the controls (P=0.04), the opposite effect was observed 
in SH-SY5Y transfectants, which expressed markedly higher 
levels of HMGB1 than the control SH-SY5Y cells (P=0.003).
Expression of PTEN in miR‑221 and ‑222 in parental control 
and transfectant SK‑N‑BE(2) and SH‑SY5Y cells. To show that 
the action of exogenous HMGB1 on miRNAs is functional, 
the expression of PTEN, a known target of miR-221/222, 
was analyzed in control and transfectant cells. Fig. 3 shows 
that PTEN expression is markedly decreased in SK-N-BE(2) 
transfectants (miR-221/222) compared with controls, while the 
addition of HMGB1 increases PTEN expression to the same 
Figure 1. Effect of HMGB1 on miR-221 and -222 expression in SK-N-BE(2) 
and SH-SY5Y cells. SK-N-BE(2) (upper panel) and SH-SY5Y cells (lower 
panel) were cultured for 24 h with or without 10 nM HMGB1. Expression 
levels of miRNAs were detected by reverse transcription-quantitative poly-
merase chain reaction. miRNA expression was quantified using the ∆∆Cq 
method and normalized to U6b small nuclear RNA expression. Histograms 
represent the mean ± standard deviation of 3 independent experiments. 
*P<0.05,  SK-N-BE(2) vs. SH-SY5Y Ctrl. **P<0.05, SK-N-BE(2) transfectants 
vs. SK-N-BE(2) transfectants + HMGB1. ***P<0.05, SH-SY5Y transfectants 
vs. SH-SY5Y transfectants + HMGB1. miR/miRNA, microRNA; Ctrl, con-
trol; HMGB1, high mobility group box 1; Ctrl, control.
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levels as the controls (P=0.008). The decreased PTEN expres-
sion in SK-N-BE(2) transfectant cells may be explained by 
the different roles of miRNAs in neuroblastoma, as the same 
miRNAs may induce proliferation or survival of certain cells 
and concurrent differentiation of others.
In SH-SY5Y cells, HMGB1 appeared to increase PTEN 
expression compared with the control cells, while it did not 
show any effect in the transfectant cells. It is of note that PTEN 
expression in control SH-SY5Y cells was markedly lower than 
in control SK-N-BE(2) cells (P=0.001), in agreement with a 
previous study (19).
HMGB1 has opposite effects on the growth of SK‑N‑BE(2) 
and SH‑SY5Y cells. Fig. 4 shows growth curves of parental 
control and transfectant SK-N-BE(2) and SH-SY5Y cells. 
The addition of 10 nM HMGB1 to SK-N-BE(2) cells for 24, 
48 and 72 h induced an increase in growth of 56, 284 and 
125%. Notably, the opposite result was obtained in SH-SY5Y 
cells cultured in the presence of HMGB1, with growth 
increasing to 28 and 75% at 24 and 48 h, but decreasing to 
0.9% at 72 h. SK-N-BE(2) cells transfected with miR-221 
and -222 antagomiRs demonstrated a decrease in growth 
compared with control cells. HMGB1 added to transfectant 
SK-N-BE(2) and SH-SY5Y cells further reduced growth 
compared with untreated transfectants.
Analysis of DNA content in parental control cells and 
transfectants of both cell lines treated with or without HMGB1 
for 24 h confirmed the growth curves results. As shown in 
Fig. 5, a high tetraploid peak was observed in SK-N-BE(2) 
cells following treatment with HMGB1, while the tetraploid 
peak was reduced in transfectant cells (A3) and there was a 
high hypodiploid peak in SK-N-BE(2) transfectant cells (A4), 
indicating cellular apoptosis. Regarding SH-SY5Y cells, the 
reduction in growth following treatment with HMGB1 was 
confirmed by the high hypodiploid peak (B2) and low tetra-
ploidy (B4) peaks observed in both transfectant and control 
cells following treatment with HMGB1.
Discussion
Transcription of miR-221 is induced by N-Myc transcrip-
tion factor (20) in MYCN-amplified SK-N-BE(2) cells. The 
present study demonstrated that miR-221 and -222 are more 
highly expressed in SK-N-BE(2) cells than in SH-SY5Y cells. 
It is known that the miR-221/222 cluster targets PTEN (21), an 
oncosuppressor gene that is considered to be one of the primary 
regulators of AKT-activating pathways. The PTEN gene is 
frequently lost on chromosome 10q2317 in various types of 
human cancer. Notably, aberrant methylation of the PTEN 
gene has been observed in neuroblastoma tissues, resulting 
in PTEN inactivation and AKT hyperactivation. Our previous 
study reported that HMGB1 decreases PTEN expression in 
thyroid cancer cell lines by cooperating with the miR-221/222 
cluster. Similarly, the present study reports that HMGB1 has 
an effect on neuroblastoma cell lines by enhancing miR-221 
and -222 expression in both MYCN-amplified and non-ampli-
fied cell lines. The growth increase induced by HMGB1 in 
SK-N-BE(2) cells may be explained by the known association 
between N-Myc transcription factor and HMGB1, which acts 
on AKT-activating pathways (22). Furthermore, the present 
study showed that HMGB1 enhances miR-221/222 expression 
and induces growth in SK-N-BE(2) cells. When miR-221/222 
expression was reduced by antisense oligonucleotides, PTEN 
expression also decreased; however, the addition of HMGB1 
for 24 h was able to re-establish PTEN function and, conse-
quently, reduce the cell growth rate. We hypothesize that 
HMGB1 exerts its action on miR-221/222 and PTEN expres-
sion as a consequence of their interaction. Furthermore, the 
Figure 3. PTEN expression in parental ctrl and microRNA-221/222 
SK-N-BE(2) and SH-SY5Y cells. SK-N-BE(2) and SH-SY5Y cells were 
cultured for 24 h with and without 10 nM HMGB1. Protein expression level 
of PTEN protein (55 kDa) was detected by western blot analysis in whole 
cell lysates. Densitometry was performed on western blot bands and each 
plot is shown underneath each band. Results are representative of 3 different 
western blot experiments. *P<0.05, SK-N-BE(2) vs. transfectants. **P<0.05, 
SK-N-BE(2) Ctrl vs. SH-5H5Y Ctrl. PTEN, phosphatase and tensin homolog; 
ctrl, control; HMGB1, high mobility group box 1.
Figure 2. HMGB1 expression in parental ctrl and transfectant SK-N-BE(2) 
and SH-SY5Y cells. SK-N-BE(2) and SH-SY5Y cells were cultured for 
24 h with and without 10 nM HMGB1. The expression level of HMGB1 
protein (28-30 kDa) was detected by western blotting in whole cell lysates. 
Densitometry was performed on the western blot bands and each plot is shown 
underneath each band. Results are representative of 3 different western blot 
experiments. *P<0.05, SK-N-BE(2) Ctrl vs. transfectants. **P<0.05, SH-SY5Y 
Ctrl vs. transfectants. HMGB1, high mobility group box 1; Ctrl, control.
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decreased PTEN expression observed in SK-N-BE(2) cells 
may be explained by the different roles of miRNAs in neuro-
blastoma, as the same miRNAs may induce both inhibition 
and potentiation of certain mRNAs in the different neuroblas-
toma lines. It is known that exogenous HMGB1 binds RAGE, 
which in turn activates intracellular pathways that lead to 
AKT activation. The present study identified a possible 
pathway through which HMGB1 increases the growth of 
SK-N-BE(2) cells, triggered by the action of miR-221/222 
on PTEN. This is supported by the observation that when 
miR-221 and -222 function are reduced by antagomiRs, 
HMGB1 increases PTEN expression. In SH-SY5Y cells, 
Figure 5. Cell cycle of control parental and transfected (A) SK-N-BE(2) and (B) SH-SY5Y cells. Parental control cells and transfectant cells (105) were seeded 
into a 6-well plate at 0 h with and without 10 nM high mobility group box 1 (HMGB1). After 24 h, cells were fixed in 70% ethanol at 4˚C for 1 h and then 
resuspended in PI solution until DNA content was determined on a cytofluorimeter. Photograms (A) and (B) both show control parental cells (top left), trans-
fected cells (top right) control parental cells treated with HMGB1 (bottom left) and transfected cells treated with HMGB1 (bottom right). Peaks: a indicates 
hypodiploid peaks, b indicates diploid peaks and c indicates tetraploid peaks. Data are representative of 3 independent experiments. PI, propidium iodide.
Figure 4. Effect of HMGB1 on the proliferation rate of parental control and transfected cells. Parental control cells and transfectant cells (105) were seeded 
into a 6-well plate at time 0 h with and without 10 nM HMGB1. At the indicated time points, cell number and cell viability of each well were counted with a 
hemocytometer. Data represent the mean ± standard deviation of 3 independent experiments. HMGB1, high mobility group box 1.
  A
  B
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which express markedly less miR-221 and -222 than 
SK-N-BE(2) cells, HMGB1 reduces growth. The differential 
expression of miR-221/222 in the two cell lines reported in 
the present study is consistent with a previous finding that 
expression of miR-21, -221 and -335 are associated with 
non-tumorigenic and neuroblastoma cell differentiation (23). 
By contrast, RAGE (24), which interacts with HMGB1, has a 
prominent role in neuritic extension in neurons (25). During 
early development, neurons undergoing differentiation 
express higher levels of RAGE and HMGB1 (26). A previous 
study (27) reported that the interaction between RAGE and 
HMGB1 potentiates retinoic acid-induced differentiation of 
SH-SY5Y cells. Furthermore, in thyroid cancer, in which 
the miR-221/222 cluster has an oncogenic effect, it has been 
shown that blocking RAGE prevents the action HMGB1 on 
miRNAs. Therefore, it is hypothesized that binding of RAGE 
with HMGB1 can regulate the actions of miR-221/222, even 
in neuroblastoma cells (unpublished data). 
In conclusion, HMGB1 acts on PTEN through the enhance-
ment of miR-221/222 in SK-N-BE(2) and SH-SY5Y cells. In 
cells transfected with miR-221/222 antagomiRs, HMGB1 was 
able to enhance PTEN expression and consequently reduce cell 
growth. The present study indicates that HMGB1 contributes 
to neuroblastoma growth and differentiation by cooperating 
with miRNAs that in turn function as oncogenes, oncosup-
pressor genes or differentiating factors. The present study 
indicates that HMGB1 signaling bridges the extracellular 
microenvironment of neuroblastoma and its tumorigenicity 
via the enhancement of miR-221/222 that in turn suppress 
the oncosuppressor PTEN. Accordingly, targeting HMGB1 
and miR-221/222 may provide novel strategies for therapies 
in neuroblastoma as extracellular HMGB1 is an inflammatory 
molecule that is implicated in the pro-tumorigenic microen-
vironment and increased expression of oncogenic miRs in 
neuroblastoma.
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